Aleksandra Rizo
Direttore/Membro del Consiglio presso SYNDAX PHARMACEUTICALS, INC.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Aleksandra Rizo is currently the President & Chief Executive Officer at Vividion Therapeutics, Inc. and a Director at Syndax Pharmaceuticals, Inc. She previously worked as an Executive Director-Strategy & Clinical Leader at Celgene Corp.
from 2018 to 2019, a Senior Director & Team Leader Compound Development at Janssen Research & Development LLC from 2008 to 2018, and as the Chief Medical Officer & Executive Vice President at Geron Corp.
from 2019 to 2022.
Rizo holds a doctorate degree from the University of Groningen, the University of Tokyo, and Saints Cyril & Methodius University of Skopje.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
15/05/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Aleksandra Rizo
Società | Posizione | Inizio |
---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 14/05/2024 |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Amministratore Delegato | 24/01/2023 |
Precedenti posizioni note di Aleksandra Rizo
Società | Posizione | Fine |
---|---|---|
GERON CORPORATION | Direttore Tecnico/Scientifico/R&S | 08/07/2022 |
CELGENE | Corporate Officer/Principal | 01/01/2019 |
Janssen Research & Development LLC
Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Corporate Officer/Principal | 01/03/2018 |
Formazione di Aleksandra Rizo
Saints Cyril & Methodius University of Skopje | Doctorate Degree |
University of Groningen | Doctorate Degree |
University of Tokyo | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
GERON CORPORATION | Health Technology |
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Janssen Research & Development LLC
Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Commercial Services |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Borsa valori
- Insiders
- Aleksandra Rizo